Holen Sie sich die Stockscreener-App
12.37
2.87%
0.345
Schlusskurs vom Vortag:
$12.02
Offen:
$11.93
24-Stunden-Volumen:
623.99K
Relative Volume:
0.61
Marktkapitalisierung:
$520.00M
Einnahmen:
$320.17M
Nettoeinkommen (Verlust:
$-36.74M
KGV:
-13.96
EPS:
-0.8856
Netto-Cashflow:
$-2.86M
1W Leistung:
+10.01%
1M Leistung:
-20.28%
6M Leistung:
+10.40%
1J Leistung:
+3.04%
1-Tages-Spanne:
$11.76
$12.47
1-Wochen-Bereich:
$11.09
$12.47
52-Wochen-Spanne:
$9.39
$16.29
Angiodynamic Inc Stock (ANGO) Company Profile
Firmenname
Angiodynamic Inc
Sektor
Telefon
(518) 798-1215
Adresse
14 PLAZA DRIVE, LATHAM
Compare ANGO vs ISRG, BDX, RMD, ALC, MDLN
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ANGO
Angiodynamic Inc
|
12.37 | 520.00M | 320.17M | -36.74M | -2.86M | -0.8856 |
ISRG
Intuitive Surgical Inc
|
452.29 | 159.78B | 11.03B | 3.16B | 3.22B | 8.7251 |
BDX
Becton Dickinson Co
|
198.91 | 54.18B | 21.37B | 1.41B | 3.07B | 3.9437 |
RMD
Resmed Inc
|
252.86 | 35.56B | 5.54B | 1.52B | 1.74B | 10.37 |
ALC
Alcon Inc
|
70.17 | 33.92B | 10.63B | 819.00M | 1.59B | 1.6577 |
MDLN
Medline Inc
|
34.09 | 29.91B | 29.14B | 1.07B | 1.05B | 1.1956 |
Angiodynamic Inc Stock (ANGO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-16 | Eingeleitet | Lake Street | Buy |
| 2024-04-05 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-09-25 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-04-17 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2021-10-15 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2021-08-20 | Eingeleitet | Oppenheimer | Perform |
| 2020-11-25 | Hochstufung | Raymond James | Mkt Perform → Strong Buy |
| 2020-04-08 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2019-04-01 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2018-04-03 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2018-01-05 | Herabstufung | Craig Hallum | Buy → Hold |
| 2017-04-07 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2017-03-30 | Herabstufung | KeyBanc Capital Mkts | Overweight → Sector Weight |
| 2017-02-08 | Eingeleitet | Barclays | Equal Weight |
| 2016-11-04 | Eingeleitet | Cantor Fitzgerald | Buy |
| 2016-04-08 | Fortgesetzt | Piper Jaffray | Neutral |
| 2016-01-08 | Bestätigt | Canaccord Genuity | Buy |
| 2015-11-10 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2015-07-24 | Eingeleitet | KeyBanc Capital Mkts | Overweight |
| 2014-06-19 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2012-10-09 | Bestätigt | Canaccord Genuity | Hold |
| 2012-06-25 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2011-07-15 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2011-07-15 | Hochstufung | Stifel Nicolaus | Hold → Buy |
| 2011-06-14 | Herabstufung | Wedbush | Neutral → Underperform |
| 2010-09-08 | Bestätigt | Wedbush | Neutral |
Alle ansehen
Angiodynamic Inc Aktie (ANGO) Neueste Nachrichten
AngioDynamics (ANGO) Advances Pancreatic Cancer Treatment with N - GuruFocus
AngioDynamics study shows survival benefit for pancreatic cancer - Investing.com
A pancreatic cancer study linked an electrical-pulse approach to 28 months’ median survival versus 15. - Stock Titan
AngioDynamics: Progress Evident, But Volatility And Margin Concerns Persist (NASDAQ:ANGO) - Seeking Alpha
Humana applies Medicare coverage rules to a non-heat treatment for some prostate and liver cancer patients. - Stock Titan
A Look at AngioDynamics Inc (ANGO) After 4.4% Decline -- GF Value $10.48 vs Price $10.90 - GuruFocus
ANGO Q1 Earnings Beat Estimates on Med Tech Growth, Revenues Up Y/Y - Zacks Investment Research
ANGIODYNAMICS INC ($ANGO) President, CEO 2026 Pay Revealed - Quiver Quantitative
AngioDynamics CLO Received Pay Boost To $1.5M Last Year - Law360
AngioDynamics (ANGO) Reports Q1 Loss, Lags Revenue Estimates - Zacks Investment Research
AngioDynamics Reports Fiscal Year 2027 First Quarter Financial Results; Continued Execution Drives Med Tech Growth and Profitability - Yahoo Finance
AngioDynamics Q1 Earnings Call Highlights - TradingView
AngioDynamics, Inc. Q1 2027 Earnings Call Summary - Yahoo Finance
With its CEO set to retire, AngioDynamics (ANGO) names a Getinge executive as successor. - Stock Titan
AngioDynamics, Inc. 2027 Q1ResultsEarnings Call Presentation (NASDAQ:ANGO) 2026-10-08 - Seeking Alpha
AngioDynamics, Inc. reports results for the quarter ended August 31Earnings Summary - TradingView
AngioDynamics Shares Fall 4.3% Despite Q1 Earnings Beat and Strong Med Tech Growth - Yahoo Finance
AngioDynamics Announces Appointment of Eric Honroth as President and Chief Executive Officer - Yahoo Finance
AngioDynamics: Fiscal Q1 Earnings Snapshot - Yahoo Finance
AngioDynamics stock slips 4% despite beating estimates on Med Tech growth - Yahoo Finance
AngioDynamics Inc (ANGO) (Q1 2027) Earnings Call Highlights: MedTech Momentum Drives 6. ... - Yahoo Finance
AngioDynamics (ANGO) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Why AngioDynamics Crashed Today - Yahoo Finance
ANGIODYNAMICS Q1 2027 Earnings Preview: Recent $ANGO Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative
AngioDynamics, Inc. (ANGO) Stock Price, News, Quote & History - Yahoo! Finance Canada
A Bronx hospital won a research award to test if scans can predict clot-removal success. - Stock Titan
A successor's appointment could set the CEO's retirement date at AngioDynamics (ANGO). There's another trigger. - Stock Titan
AngioDynamics Fiscal 2026 Net Loss Widens to $36.7 Million - Minichart
Sales reached $320.2 million at AngioDynamics (ANGO). Five executives received cash bonuses. - Stock Titan
AngioDynamics, Inc. (ANGO) stock price, news, quote and history - Yahoo Finance UK
AngioDynamics to Report Fiscal 2027 First Quarter Results on October 8, 2026 - Yahoo Finance Australia
AngioDynamics to Report Fiscal 2027 First Quarter Results on October 8, 2026 - Yahoo Finance
AngioDynamics, Inc. expected to post a loss of 11 cents a shareEarnings Preview - TradingView
How Angiodynamics Inc. (ANGO) Affects Rotational Strategy Timing - Stock Traders Daily
AngioDynamics Inc. (ANGO) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
387,188 Shares in AngioDynamics, Inc. $ANGO Bought by Western Standard LLC - MarketBeat
AngioDynamics (ANGO) Up 8.9% Since Last Earnings Report: Can It Continue? - Yahoo Finance
AngioDynamics, Inc. (ANGO) Presents at Canaccord Genuity's 46th Annual Growth ConferenceSlideshow - Seeking Alpha
AngioDynamics, Inc. (ANGO) Stock Analysis: Uncovering a 32% Potential Upside with Robust Buy Ratings - DirectorsTalk Interviews
AngioDynamics SmartPort Infection Lawsuit Alleges Defective Port Caused Sepsis - aboutlawsuits.com
AngioDynamics, Inc. $ANGO Shares Purchased by Lazard Asset Management LLC - MarketBeat
Senior Vice President of Regulatory Affairs Warren Nighan Sold A Bunch Of Shares In AngioDynamics - simplywall.st
Segall Bryant & Hamill LLC Trims Stock Position in AngioDynamics, Inc. $ANGO - MarketBeat
AngioDynamics, Inc. (NASDAQ:ANGO) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
AngioDynamics (ANGO) SVP Warren Nighan Jr. sells 23,370 shares at $14.72 - Stock Titan
AngioDynamics (NASDAQ: ANGO) insider plans $344K sale of equity awards - Stock Titan
AngioDynamics Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Live webcast set for AngioDynamics' Aug. 11 presentation - Stock Titan
AngioDynamics Inc (ANGO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
AngioDynamics, Inc. Revenue Breakdown – NASDAQ:ANGO - TradingView
Finanzdaten der Angiodynamic Inc-Aktie (ANGO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Angiodynamic Inc-Aktie (ANGO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| WARREN NIGHAN | Officer |
Jul 30 '26 |
Proposed Sale |
14.72 |
23,370 |
344,004 |
0 |
| Piccinini Laura | SVP International |
Jul 22 '26 |
Option Exercise |
0.00 |
8,047 |
0 |
86,435 |
| Nighan Warren JR | SVP Quality and Regulatory |
Jul 22 '26 |
Option Exercise |
0.00 |
5,694 |
0 |
89,786 |
| Trowbridge Stephen A | EVP and CFO |
Jul 22 '26 |
Option Exercise |
0.00 |
16,296 |
0 |
314,115 |
| Clemmer James C | President and CEO |
Jul 22 '26 |
Option Exercise |
0.00 |
52,358 |
0 |
889,176 |
| Campbell Chad Thomas | SVP/GM, Vascular Access |
Jul 22 '26 |
Option Exercise |
0.00 |
6,466 |
0 |
111,006 |
| Weiss Lawrence T | SVP, Chief Legal Officer |
Oct 21 '25 |
Buy |
11.81 |
10,000 |
118,100 |
93,597 |
| Trowbridge Stephen A | EVP and CFO |
Oct 13 '25 |
Buy |
11.16 |
890 |
9,932 |
256,629 |
| Clemmer James C | President and CEO |
Oct 09 '25 |
Buy |
11.15 |
10,000 |
111,500 |
882,529 |
2.19%
8.68%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):